JPRN-jRCT2051190027进行中（未招募）1 期
A sing le-arm, phase I study of ramucirumab in combination with erlotinib or osimertinib in previously untreated patients with EGFR mutantion-posit ive metastatic Non-small cell lung cancer with brain metastases - RELAY-Brain
Kaneda Hiroyasu0 个研究点目标入组 6 人开始时间: 2019年6月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •The study will enroll male or female patients, 20 years of age or older. Main inclusion criteria include: metastatic NSCLC patients with asymptomatic/incidental brain metastases who are eligible for first-line treatment with erlotinib or osimertinib based on previously documented evidence of tumors that have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, ECOG PS is 0-1.
排除标准
- •Key exclusion criteria include: patients with known T790M mutation; symptomatic CNS lesions; ophthalmologic abnormalities; active interstitial lung disease; and any prior systemic chemotherapy for advanced or metastatic NSCLC, including prior TKI therapy for any stage.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Study of Ramucirumab in Combination with Weekly Docetaxel in Patients with Lung Cancer Following Disease Progression after Prior Platinum-based ChemotherapyStage IV non-small cell lung cancer (NSCLC)MedDRA version: 19.0Level: LLTClassification code 10025048Term: Lung cancer non-small cell recurrentSystem Organ Class: 100000004864EUCTR2016-001317-25-ESilly S.A.50
进行中（未招募）
1 期
A Phase 2 Study of Ramucirumab in Combination with Weekly Docetaxel in Patients with Lung Cancer Following Disease Progression after Prior Platinum-based ChemotherapyEUCTR2016-001317-25-ITELI LILLY & COMPANY, LILLY CORPORATE CENTER50
未知
1 期
Phase 1b Study of Ramucirumab in Combination With Fluoropyrimidines and Platinum-Based Agents in Japanese Patients With Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaStomach NeoplasmsJPRN-jRCT2080222764Eli Lilly Japan K.K.
未知
2 期
A Phase 2 Study of Ramucirumab in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First Line Platinum- or Fluoropyrimidine-Containing Combination Therapy in Japanese PatientsGastric CancerJPRN-jRCT2080222292Eli Lilly Japan K.K.
进行中（未招募）
1 期
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid TumorsPediatric Solid TumorCNS MalignanciesEUCTR2021-000364-30-Outside-EU/EEAEli Lilly and Company